BGI Group

Next-Generation Sequencing Emerging Clinical Applications and Global Markets, with Profiles of Leading Players Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies and BGI Genomics - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024
Biotechnology, Genetics, Health, Agilent Technologies, BGI Group, Genetic disorder, Magnis, Illumina, Inc., DSM-IV codes, Genetic variation, Liquid biopsy, QIAGEN, Genomics, NGS, Marker beacon, Thermo Fisher Scientific, BGI, Fertilisation, Noninvasive prenatal testing, Genome, Informatics, CTC, Research, DNA, Medical device

The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The NGS platform enables companies to expand the menu of disorders/diseases over time after initial launch of a test.
  • The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents, and companies.
  • This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing.

"The TopBrand 2023 World's Top 500 Brand Figures" Released, Elon Musk, Bill Gates, and Taylor Swift Rank in the Top Three

Retrieved on: 
Friday, February 2, 2024
Secondary school, Senior, MPV, Male, WH Group, Research, Car, BYD, Government, NBA, NVIDIA, Science, BGI Group, Peking University, Amazon, LeBron James, National school, Volvo, Automotive industry, Microsoft, Speech, Geely, Executive, Female, Social responsibility, Gree Electric, ALS, Woman

In the "TopBrand 2023 World's Top 500 Brand Figures," the top seven spots were all occupied by individuals from the United States.

Key Points: 
  • In the "TopBrand 2023 World's Top 500 Brand Figures," the top seven spots were all occupied by individuals from the United States.
  • Cristiano Ronaldo, the Portuguese football superstar, rounded out the top ten as the "goalkeeper" of the world's brand figures.
  • Dr. Wang Yong, Chairman of the Topbrand Union and founder and chairman of the China Brand Festival, announced the "TopBrand 2023 World's Top 500 Brand Figures" list.
  • Furthermore, at this summit, the "TopBrand China's Top Ten Brand Figures of the Year" was announced for the 18th consecutive year.

In-vitro Diagnostics Market to grow by USD 33.16 billion from 2021 to 2026 | The rising geriatric population with chronic and infectious diseases drives the market growth - Technavio

Retrieved on: 
Wednesday, December 13, 2023
Abbott Laboratories, Sample, Thermo Fisher Scientific, Prevalence, DiaSorin, Immunoassay, ROW, Hepatitis B virus, BGI Group, Laboratory, Patient, HBV, Mindful Scientific Inc., Danaher Corporation, Infection, Illumina, Inc., Quest Diagnostics, Virus, Cancer, Ageing, HCV, QIAGEN, IVD, Diabetes, Agilent Technologies, Retail, Medical device, Hematology, Geography

NEW YORK, Dec. 12, 2023 /PRNewswire/ -- The in-vitro diagnostic market size is estimated to grow by USD 33.16 billion from 2021 to 2026.

Key Points: 
  • NEW YORK, Dec. 12, 2023 /PRNewswire/ -- The in-vitro diagnostic market size is estimated to grow by USD 33.16 billion from 2021 to 2026.
  • The rising geriatric population with chronic and infectious diseases drives the in-vitro diagnostics (IVD) market growth during the forecast period.
  • Hence, the increasing prevalence of diseases in the aging population is expected to drive market growth during the forecast period.
  • Key challenges - Stringent regulatory guidelines for in-vitro diagnostics manufacturers can pose a significant threat which can hinder the in-vitro diagnostics (IVD) market growth during the forecast period.

In-vitro Diagnostics Market to grow by USD 33.16 billion from 2021 to 2026| The rising geriatric population with chronic and infectious diseases drives the market growth- Technavio

Retrieved on: 
Monday, December 4, 2023
Abbott Laboratories, Sample, Thermo Fisher Scientific, Prevalence, DiaSorin, Immunoassay, ROW, Hepatitis B virus, BGI Group, Laboratory, Patient, HBV, Mindful Scientific Inc., Danaher Corporation, Infection, Illumina, Inc., Quest Diagnostics, Virus, Cancer, Ageing, HCV, QIAGEN, IVD, Diabetes, Agilent Technologies, Retail, Medical device, Hematology, Geography

NEW YORK, Dec. 3, 2023 /PRNewswire/ -- The in-vitro diagnostic market size is estimated to grow by USD 33.16 billion from 2021 to 2026.

Key Points: 
  • NEW YORK, Dec. 3, 2023 /PRNewswire/ -- The in-vitro diagnostic market size is estimated to grow by USD 33.16 billion from 2021 to 2026.
  • The rising geriatric population with chronic and infectious diseases drives the in-vitro diagnostics (IVD) market growth during the forecast period.
  • Hence, the increasing prevalence of diseases in the aging population is expected to drive market growth during the forecast period.
  • The in-vitro diagnostics market report provides critical information and factual data, with a qualitative and quantitative study of the market based on market drivers and limitations as well as future prospects.

75 Percent of Azerbaijani Women Know Little About Thalassemia Health Risks: BGI Insight

Retrieved on: 
Wednesday, November 29, 2023
Disease, Patient, Genomics, BGI Group, Thalassemia

Dr. Agha Rza Aghayev, Head of Medical Genetics Department, National Hematology and Transfusiology Center, analyzes findings from the Global 2023 State of Thalassemia Awareness Report

Key Points: 
  • Dr. Agha Rza Aghayev, Head of Medical Genetics Department, National Hematology and Transfusiology Center, analyzes findings from the Global 2023 State of Thalassemia Awareness Report
    TASHKENT, Azerbaijan, Nov. 29, 2023 /PRNewswire/ -- The Azerbaijan Thalassemia Center estimates there are more than one million carriers of thalassemia in the country.
  • Treatments for moderate to severe thalassemia is often costly and impose challenges on patients, their families, and the healthcare system.
  • Recognizing these challenges, the Azerbaijan Thalassemia Center and BGI Genomics sealed a Collaboration Agreement in September 2022 to improve thalassemia screening in Azerbaijan through genetic technology.
  • Dr. Agha Rza Aghayev, Head of Medical Genetics Department, National Hematology and Transfusiology Center, shared his views on BGI Genomics Global 2023 State of Thalassemia Awareness Report 's findings related to Azerbaijan and offer greater insight to improve awareness of this disease.

94.1 percent of Kuwaiti Women Consider Thalassemia Screening after Learning about Health Risks

Retrieved on: 
Friday, November 17, 2023
Woman, GM, Behavior, Policy, Prevalence, Genetic counseling, Hospital, Learning, Patient, Genomics, BGI Group, PGD, BGI, Female, Knowledge, Online shopping, Medical device, Thalassemia

RIYADH, Saudi Arabia, Nov. 17, 2023 /PRNewswire/ -- To facilitate greater understanding of thalassemia, a hereditary hemoglobinopathy, BGI Genomics today released its State of Thalassemia Awareness Report. This report assesses the level of knowledge and attitudes related to the associated health risks, thalassemia carrier screening, and genetic counseling for carriers. 1,847 female respondents from six countries with high thalassemia prevalence were surveyed: Azerbaijan, China, Indonesia, Kuwait, Saudi Arabia, and Thailand.

Key Points: 
  • This report assesses the level of knowledge and attitudes related to the associated health risks, thalassemia carrier screening, and genetic counseling for carriers.
  • 1,847 female respondents from six countries with high thalassemia prevalence were surveyed: Azerbaijan, China, Indonesia, Kuwait, Saudi Arabia, and Thailand.
  • 94.1% of Kuwaiti women consider screening after learning about associated thalassemia health risks and costs which is higher than the global average of 84.5%.
  • Thalassemia carriers are more open to genetic counseling: If both partners are thalassemia carriers, 50.8% of women can persuade their partners to seek genetic counseling and consider PGD.

Global and Regional Rare Disease Genetic Testing Market Analysis & Forecasts Report 2023-2033 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 9, 2023
Health, Genetics, Diagnosis, Incidence, Parent, Hospital, DSM-IV codes, Physician, Exome, Plasma, Research, SRL Diagnostics, Genome, Prevalence, PCR, BGI Group, NGS, DNA, CVS, Risk, SNV calling from NGS data, Sanger, Massive parallel sequencing, Metabolism, Amniocentesis, Genetic code, Disease, State Key Laboratories, R, Inherit, Genomics, Patient, Polymerase chain reaction, WES, WGS, Genetic counseling, Growth, Genetic testing, Region, National Centre for Foreign Animal Disease, Gene, Rare, Chromosome, Fetus, Cardiogenic shock, Serum, Birth, Gastroenterology, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Dietary supplement

The "Rare Disease Genetic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Offering, Specialty Type, Sample Type, Trait Type, Technology, Age Group, End User, and Country Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rare Disease Genetic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Offering, Specialty Type, Sample Type, Trait Type, Technology, Age Group, End User, and Country Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The global market for rare disease genetic testing encompasses an array of panels and tests that excel in detecting rare diseases.
  • The global rare disease genetic testing market has experienced remarkable growth, driven by the escalating demand for early detection of rare diseases.
  • Moreover, a maximum number of rare disease testing is done there, due to which these regions hold the maximum share in the global rare disease genetic testing market.

Global and Regional Rare Disease Genetic Testing Market Report 2023-2033: Early Detection Demand and Innovative Systems Usher in New Era for Rare Disease Genetic Testing

Retrieved on: 
Tuesday, October 3, 2023
Chromosome, DNA, Sanger, National Centre for Foreign Animal Disease, Gastroenterology, Prevalence, BGI Group, DSM-IV codes, Serum, Disease, Fetus, Genomics, Parent, Hospital, Cardiogenic shock, SRL Diagnostics, NGS, Amniocentesis, CVS, Genetic testing, Research, Birth, Genetic code, Exome, Incidence, Genetic counseling, Plasma, Metabolism, Patient, Polymerase chain reaction, Physician, Risk, State Key Laboratories, WGS, Inherit, Growth, Diagnosis, Region, R, Rare, WES, SNV calling from NGS data, Massive parallel sequencing, Gene, PCR, Genome, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Dietary supplement

The global market for rare disease genetic testing encompasses an array of panels and tests that excel in detecting rare diseases.

Key Points: 
  • The global market for rare disease genetic testing encompasses an array of panels and tests that excel in detecting rare diseases.
  • Among the most prevalent rare disease genetic testing panels are those tailored for gastroenterology, endocrine and metabolic disorders, and neurological diseases.
  • The global rare disease genetic testing market has experienced remarkable growth, driven by the escalating demand for early detection of rare diseases.
  • Moreover, a maximum number of rare disease testing is done there, due to which these regions hold the maximum share in the global rare disease genetic testing market.

Exploring New Collaborative Opportunities! The Indonesia-China Healthcare and Biotech Investment Forum Successfully Held

Retrieved on: 
Monday, July 31, 2023
Partnership, Medical device, Health care, Speech, BGI Group, Chinese Industrial Cooperatives, BeiGene, Kimia Farma, BGI, Shangri-La Hotels and Resorts, Technology policy, Genomics, CanSino Biologics, Global Health, Ministry, Republic, Diplomatic mission, Legislation on Chinese Indonesians, KIKT, Legend Holdings, Tsinghua University, International business, Ecosystem, Ministry of Health (Indonesia), Policy, Commerce, Management, Pharmaceutical industry, China–Indonesia relations, Health

A total of 120 people, including Indonesian government officials, scholars, business people and leading Chinese healthcare companies, attended the event to jointly discuss the direction and opportunities for the development of healthcare and biotech in China and Indonesia.

Key Points: 
  • A total of 120 people, including Indonesian government officials, scholars, business people and leading Chinese healthcare companies, attended the event to jointly discuss the direction and opportunities for the development of healthcare and biotech in China and Indonesia.
  • The forum was chaired by Mr. Jafar WANG, Co-Chief Investment Officer of Legend Capital, who mentioned Legend Capital's latest "Ecosystem plus" strategy in healthcare, and hoped to collaborate with the excellent healthcare enterprises in China and Indonesia to build an open, innovative, and international ecosystem through this forum.
  • Mr. Garibaldi Thohir, Chairman of Indonesia Chamber of Commerce and Industry Bilateral Committee of China (KIKT), Mr. H.E.
  • The Minister of Health Indonesia, Budi Gunadi Sadikin, delivered a keynote speech on "Healthcare Policy and Planning in Indonesia".

BGI CEO Yin Ye Advocates for Global Technology Sharing

Retrieved on: 
Wednesday, July 5, 2023
Vaccine, BGI Group, Biotechnology, COVID-19, Infection, BGI, World Health Organization, Research, Cell, Participation, Certification, Laboratory, Human, IVD, Human Genome Project, PCR, Genome

SHENZHEN, China, July 5, 2023 /PRNewswire/ -- Speaking on a panel at the 10th Arab-China Business Conference in Riyadh, Saudi Arabia, Dr Yin Ye, BGI Group CEO, reinforced the importance of making technological advancements available to everyone through scientific sharing to benefit humanity.

Key Points: 
  • SHENZHEN, China, July 5, 2023 /PRNewswire/ -- Speaking on a panel at the 10th Arab-China Business Conference in Riyadh, Saudi Arabia, Dr Yin Ye, BGI Group CEO, reinforced the importance of making technological advancements available to everyone through scientific sharing to benefit humanity.
  • The COVID-19 pandemic demonstrated the importance of the world coming together to share technology and information to solve a critical health issue.
  • "During the pandemic, if we did not share the technology, the public health applications, vaccines and IVD kits, then the virus would definitely occupy the world," said Dr Yin.
  • BGI Group strongly believes that mankind can only benefit through greater sharing of technology and information as this can help doctors understand diseases and population traits that may result in diseases.